We are live on !
Find out more
SL
Siren LLC Portfolio holdings
AUM
$4.94B
Turnover
27.78%
1-Year Est. Return
244.43%
This Fund
S&P 500
This Quarter Est. Return
+34.74%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.33B
(+37%)
Cap. Flow
+$314M
Cap. Flow % of AUM
Cap. Flow %
6.35%
Top 10 Holdings %
Top 10 Hldgs %
44.63%
Holding
126
New
26
Increased
32
Reduced
21
Closed
9
Avg Time Held
Equity + Options
0.9
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$82.7M |
| 2 |
Abivax
ABVX
|
+$65.2M |
| 3 |
Hemab Therapeutics
COAG
|
+$57.6M |
| 4 |
Relay Therapeutics
RLAY
|
+$53M |
| 5 |
Kailera Therapeutics
KLRA
|
+$48.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$60.4M |
| 2 |
Edgewise Therapeutics
EWTX
|
+$42.9M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$41.8M |
| 4 |
Revolution Medicines
RVMD
|
+$30.8M |
| 5 |
Kymera Therapeutics
KYMR
|
+$21.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.94% |
| 2 | Technology | 3.57% |
| 3 | Communication Services | 1.85% |
| 4 | Financials | 0.87% |
| 5 | Consumer Discretionary | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
monday.com
MNDY
$3.97B
| $3.08M | 0.06% |
42,500
+17,500
| +70% | +$1.28M |
2025 Q3
3 quarters
|
|
102
Zoetis
ZTS
$33.9B
| $2.52M | 0.05% |
+35,000
| New | +$3.29M |
2026 Q2
0 quarters
|
|
103
Workiva
WK
$4.65B
| $2.18M | 0.04% |
45,000
-47,500
| -51% | -$2.45M |
2024 Q4
6 quarters
|
|
104
Netflix
NFLX
$273B
| $1.78M | 0.04% |
+25,000
| New | +$2.2M |
2026 Q2
0 quarters
|
|
105
Kalaris Therapeutics
KLRS
$48.1M
| $1.77M | 0.04% |
435,798
| – | – |
2024 Q3
7 quarters
|
|
106
Quantinuum Inc
QNT
$1.17B
| $1.63M | 0.03% |
+20,000
| New | +$1.29M |
2026 Q2
0 quarters
|
|
107
Rani Therapeutics
RANI
$59.6M
| $1.52M | 0.03% |
2,000,000
| – | – |
2025 Q4
2 quarters
|
|
108
Tesla
TSLA
$1.36T
| $1.47M | 0.03% |
3,500
-18,000
| -84% | -$7.16M |
2025 Q1
5 quarters
|
|
109
KE Holdings
BEKE
$20.6B
| $1.45M | 0.03% |
100,000
| – | – |
2024 Q3
7 quarters
|
|
110
Entera Bio
ENTX
$541M
| $1.3M | 0.03% |
+736,457
| New | +$921K |
2026 Q2
0 quarters
|
|
111
Medline Inc
MDLN
$34.9B
| $986K | 0.02% |
25,000
| – | – |
2025 Q4
2 quarters
|
|
112
Lumentum
LITE
$46.2B
| $905K | 0.02% |
+1,055
| New | +$941K |
2026 Q2
0 quarters
|
|
113
Figma
FIG
$9.8B
| $904K | 0.02% |
50,000
| – | – |
2025 Q3
3 quarters
|
|
114
Gossamer Bio
GOSS
$60.9M
| $857K | 0.02% |
65,112
| – | – |
2024 Q3
7 quarters
|
|
115
Fox Class A
FOXA
$28.5B
| $522K | 0.01% |
+10,000
| New | +$618K |
2026 Q2
0 quarters
|
|
116
AT&T
T
$147B
| $518K | 0.01% |
+25,000
| New | +$620K |
2026 Q2
0 quarters
|
|
117
Nu Holdings
NU
$56.7B
| $334K | 0.01% |
25,000
| – | – |
2026 Q1
1 quarter
|
|
118
Bicycle Therapeutics
BCYC
$244M
| – | – |
-1,560,882
| Closed | -$7.24M | – |
|
|
CNTA
119
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-1,053,464
| Closed | -$41.8M | – |
|
120
Fulcrum Therapeutics
FULC
$288M
| – | – |
-2,350,000
| Closed | -$18M | – |
|
121
Micron Technology
MU
$743B
| – | – |
-6,000
| Closed | -$2.03M | – |
|
122
uniQure
QURE
$1.47B
| – | – |
-1,000,000
| Closed | -$16.4M | – |
|
123
Wave Life Sciences
WVE
$635M
| – | – |
-2,450,000
| Closed | -$17.8M | – |
|
124
Amer Sports
AS
$18.2B
| – | – |
-50,000
| Closed | -$1.65M | – |
|
125
Primo Brands
PRMB
$8.02B
| – | – |
-50,000
| Closed | -$942K | – |
|
Similar funds
Siren LLC's Q2 2026 Portfolio in Review
As of Q2 2026, Siren LLC held 126 positions worth $4.94B, up 37% from $3.61B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Siren LLC deployed $314M of net new capital in Q2 2026, opening 26 new positions and adding to 32 existing holdings. Its largest new stake was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Scholar Rock, an estimated $60.4M trimmed.
- Siren LLC's largest Q2 2026 buy was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
- Siren LLC added most to Enliven Therapeutics in Q2 2026, an estimated $43.7M increase.
- Siren LLC's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $60.4M.
- Siren LLC fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.8M.
- Siren LLC's ten largest holdings make up 45% of its $4.94B portfolio in Q2 2026.
- Siren LLC opened 26 new positions and closed 9 in Q2 2026.
- Siren LLC's portfolio value rose 37% quarter-over-quarter to $4.94B.
Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.